Purpose: It has been demonstrated that large numbers of tumor-specific T cells for adoptive
cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous …

PURPOSE: We did a phase I dose-escalation trial to evaluate the feasibility and safety of
intratumoral injections of C Cure 709, an allogeneic, continuous CTL cell line that, restricted …

Adoptive T cell therapy, involving the ex vivo selection and expansion of antigen-specific T
cell clones, provides a means of augmenting antigen-specific immunity without the in vivo …

The tumor-associated-Ag MART-1 is expressed by most human melanomas. The genes
encoding an αβ TCR from a MART-1-specific, HLA-A2-restricted, human T cell clone have …

Purpose The adoptive transfer of in vitro generated tumor antigen-specific cytotoxic T
lymphocytes (CTL) provides a promising approach to the immunotherapy of cancer. A phase …

This report describes a phase I study of the adoptive transfer of cloned melanoma antigen–
specific T lymphocytes for therapy of patients with advanced melanoma. Clones were …

Dendritic cells (DCs) loaded with killed allogeneic tumors can cross-prime tumor-specific
naive CD8+ T cells in vitro, thereby providing an option to overcome human leukocyte …

Adoptive cell transfer therapy using tumor-infiltrating lymphocytes for patients with metastatic
melanoma has demonstrated significant objective response rates. One major limitation of …

Adoptive immunotherapy of cancer requires the generation of large numbers of tumor
antigen–reactive T cells for transfer into cancer patients. Genes encoding tumor antigen …

T-cell receptor (TCR) gene transfer for cancer immunotherapy is limited by the availability of
large numbers of tumor-specific T cells. TCR α and β chains were isolated from a highly lytic …